Skip to main content
. 2023 Nov 10;66:102303. doi: 10.1016/j.eclinm.2023.102303

Fig. 2.

Fig. 2

Maximum size change in the target lesion from baseline (n = 32). The presence and type of EGFR mutations, histology, and whether the use of taxane and bevacizumab in the previous therapy are shown in the bottom row. PR; partial response, SD; stable disease, PD; progressive disease, EGFR; epidermal growth factor receptor, NSCLC-NOS; non-small cell lung cancer, not-otherwise specified.